First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

被引：0

作者：

Wolfgang Janni

Emilio Alba

Thomas Bachelot

Sami Diab

Miguel Gil-Gil

Thaddeus J. Beck

Larisa Ryvo

Rafael Lopez

Michaela Tsai

Francisco J. Esteva

Pilar Zamora Auñón

Zdenek Kral

Patrick Ward

Paul Richards

Timothy J. Pluard

Santosh Sutradhar

Michelle Miller

Mario Campone

机构：

[1] University of Ulm,Department of Internal Medicine, Hematology and Oncology

[2] Hospital Universitario Virgen de la Victoria,undefined

[3] IBIMA,undefined

[4] Centre Léon Bérard,undefined

[5] Rocky Mountain Cancer Centers,undefined

[6] Institut Català d’Oncologia,undefined

[7] IDIBELL,undefined

[8] L’Hospitalet de Llobregat,undefined

[9] Highlands Oncology Group,undefined

[10] Tel Aviv Sourasky Medical Center,undefined

[11] Hospital Clínico Universitario e Instituto de Investigación Santiago-CIBERONC,undefined

[12] Minnesota Oncology,undefined

[13] Perlmutter Cancer Center at New York University Langone Health,undefined

[14] Hospital Universitario La Paz,undefined

[15] University Hospital Brno,undefined

[16] Oncology Hematology Care,undefined

[17] Oncology Hematology Associates of Southwest Virginia,undefined

[18] Saint Luke’s Health System,undefined

[19] Novartis Pharmaceuticals Corporation,undefined

[20] Centre René Gauducheau,undefined

[21] Institut de Cancérologie de l’Ouest,undefined

来源：

Breast Cancer Research and Treatment | 2018年 / 169卷

关键词：

Ribociclib; Advanced breast cancer; MONALEESA-2; CDK4/6;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：469 / 479

页数：10

共 316 条

[1]

Gnant M(2012)The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer Curr Oncol Rep 15 14-23

[2]

Gnant M(2012)Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition Expert Rev Anticancer Ther 12 1579-1589

[3]

Cardoso F(2014)ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Ann Oncol 25 1871-1888

[4]

Costa A(2012)Abrogating endocrine resistance by targeting ERalpha and PI3K in breast cancer Front Oncol 2 145-247

[5]

Norton L(2011)Mechanisms of endocrine resistance in breast cancer Annu Rev Med 62 233-28

[6]

Senkus E(2016)The PI3K/AKT pathway as a target for cancer treatment Annu Rev Med 67 11-351

[7]

Aapro M(2011)ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer Cancer Discov 1 338-70

[8]

André F(2012)Comprehensive molecular portraits of human breast tumours Nature 490 61-439

[9]

Barrios CH(2016)Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Lancet Oncol 17 425-35

[10]

Bergh J(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 25-219

← 1 2 3 4 5 6 7 8 9 10 →